Cormedix Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cormedix Inc. on March 22, 2018, reporting an event that occurred on March 19, 2018. The filing details the entry into a material definitive agreement with Elizabeth Masson, who was appointed as Executive Vice President and Head of Clinical Operations. Prior to this appointment, Ms. Masson had served as a consultant to the company since late November 2017.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or liquidity data. The only financial figures disclosed relate to the executive compensation package:
- Base Salary: $280,000 annually.
- Annual Bonus: Up to 30% of base salary, contingent on company and personal objectives.
- Equity Grant: Stock options to purchase 310,000 shares of common stock (186,000 time-vested over four years; 124,000 milestone-vested).
- Severance (Non-Cause Termination): Nine months of base salary and benefits, plus prorated bonus and COBRA premium support.
- Severance (Change in Control): Nine months of base salary and full target bonus, plus accelerated vesting of all unvested options (excluding unmet milestones).
Material Changes
The primary material change is the formalization of Ms. Masson's role from consultant to full-time executive. The agreement establishes a three-year initial term with automatic one-year renewals unless terminated with 90 days' notice. The filing defines specific conditions for "Cause" and "Good Reason" terminations, which trigger distinct severance and equity acceleration provisions.
Outlook, Risks, and Contingencies
Management Commentary: The company intends to file the full employment agreement as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending March 31, 2018.
Restrictive Covenants: Ms. Masson is subject to a non-compete restriction for 12 months following separation. She is prohibited from engaging in the development or commercialization of preventive anti-infective products that compete with Neutrolin, taurolidine-containing products, or other products actively developed by Cormedix within the U.S. and European Union.
Contingencies: Severance benefits are conditioned upon the executive executing a release of claims against the company and its affiliates.
Key Facts for Investor Verification
- Verify the total number of outstanding shares and the potential dilution impact of the 310,000 new stock options granted.
- Review the upcoming Form 10-Q for the full text of the employment agreement to confirm specific milestone definitions for the 124,000 milestone-vested options.
- Assess the company's cash burn rate relative to the new fixed annual salary obligation of $280,000 plus potential bonus and severance liabilities.
- Confirm the status of the company's clinical operations pipeline, specifically regarding Neutrolin and taurolidine products, given the executive's new focus.